Tolerance and Efficacy of Targeted Therapies After Immunotherapy for Advanced Non-Small Cell Lung Cancers Harboring Oncogenic Alterations: The GFPC-TOXIMAD Study. (PubMed, Curr Oncol) - Sep 25, 2026 - "According to this analysis, sequential ICI-targeted therapy use for advanced NSCLC appeared to be associated with more grade 3-5 AEs."
IO biomarker • Journal • Retrospective data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • BRAF • EGFR • MET
|
|
Anne Laure Désage; Aurélie Swalduz; Catherine Daniel; Charles Ricordel; Christos Chouaid; Eric Huchot; Florian Guisier; Helene Doubre; Hubert Curcio; Jean-Bernard Auliac; Jessica Nguyen; Laurence Bigay-Game; Laurent Greillier; Lionel Falchero; Olivier Bylicki; Thomas Pierret
|